Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Frechen – page 16

1 443 clinical trials in Frechen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frechen at a glance
1 443
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 443 trials in Frechen

Open in trial search

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
  • Sponsor:TargED Biopharmaceuticals B.V.

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:R2R01
  • Sponsor:River 2 Renal Corp.

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim International GmbH

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Lonapegsomatropin
  • Sponsor:Ascendis Pharma Endocrinology Division A/S

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5148
  • Sponsor:AstraZeneca AB

Proctitis

Recruiting

Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

A safety study of romosozumab in children and adolescents with osteogenesis imperfecta

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Romosozumab
  • Sponsor:Amgen Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Frechen

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), evaluating new combination therapies with venetoclax and comparing different treatment durations based on measurable residual disease.

  • Treatment Duration Optimization
  • Combination Therapy Assessment
  • Disease Progression Monitoring

Innovative approaches in blood cancer treatment aimed at improving patient outcomes through personalized therapy duration.

02 Supportive Cancer Care

Investigation into preventing and managing chemotherapy-induced polyneuropathy (CIPN) using Aconite Pain Oil, with a focus on improving quality of life for cancer patients undergoing chemotherapy treatment.

  • Neuropathy Prevention
  • Symptom Management
  • Quality of Life Enhancement

Novel approaches to reducing chemotherapy side effects and maintaining treatment effectiveness.

03 Precision Medicine

Advanced research incorporating artificial intelligence to evaluate treatment resistance in patients with polycythemia vera, focusing on predicting hydroxyurea resistance patterns.

  • AI-Based Prediction Models
  • Treatment Resistance Analysis
  • Personalized Treatment Strategies

Integration of machine learning with clinical practice to optimize treatment selection and patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.